Work

LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.534

Authors: Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan Wade Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Warren Rasco, Scott P. Myrand, Palaniappan Kulanthaivel, Joan M. Andrews, Martin Frenzel, Damien Cronier, Edward M. Chan, Keith Flaherty, Patrick Y. Wen, Geoffrey Shapiro

Institutions: South Texas Accelerated Research Therapeutics, University of California, Los Angeles, Dana-Farber Cancer Institute, Eli Lilly (United States), Harvard University, Massachusetts General Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2529617359

Cites:

Cited by: 42

Related to: 10